Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million
· zevra therapeutics
AI Briefing
- Zevra Therapeutics sells SDX portfolio to Commave Therapeutics for $50 million
- Companies resolve lawsuit in Delaware
- No further details available
Advertisement